T cells in type 1 diabetes: mechanisms of β-cell autoimmunity, innate-adaptive immune crosstalk, and translational immunotherapy
4 affiliations
- 1Department of Internal Medicine, Berkshire Medical Center
- 2Department of Radiation Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
- 3Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
- 4Faculty of Medicine, Al-Azhar University
Abstract
Type 1 diabetes (T1D) is an autoimmune disease in which immune responses drive the destruction of insulin-producing pancreatic β-cells, ultimately resulting in lifelong insulin dependence. Although T cells are central mediators of β-cell autoimmunity, growing evidence shows that innate immune cells, including dendritic cells, macrophages, and natural killer (NK) cells, play essential roles in initiating, shaping, and sustaining pathogenic adaptive responses within the islet microenvironment. Both CD4 ⁺ helper and CD8 ⁺ cytotoxic T lymphocytes contribute to β-cell injury through the production of inflammatory cytokines, direct cytotoxicity, and disruption of self-tolerance. At the same time, regulatory T cells exhibit reduced numbers and/or impaired suppressive function, thereby further accelerating autoimmune progression. Recent advances in animal models, single-cell transcriptomics, spatial immune profiling, and T cell receptor sequencing have refined our understanding of autoreactive repertoires, antigen specificity, and bidirectional crosstalk between innate and adaptive immune compartments. At the translational level, immune signatures are emerging as tools for disease prediction and patient stratification, while therapeutic strategies ranging from anti-CD3 monoclonal antibodies to tolerogenic vaccines and adoptive Treg therapies are moving from preclinical development into clinical evaluation. The clinical success of teplizumab as the first disease-modifying therapy for T1D reinforces the value of targeting immune pathways, but durable remission across diverse patient groups remains a major challenge. This review synthesizes recent advances in the immunobiology of T cells in T1D, emphasizing their functional interplay with innate immune cells, tracing the path from mechanistic discovery to clinical translation, and highlighting future directions for precision immunotherapy.
Related
- Trained immunity in cancer immunotherapy and vaccine development: mechanisms, evidence gaps, and translational opportunities
- Targeting inhibitory phagocytosis checkpoints in cancer immunotherapy: mechanisms, therapeutic strategies, and translational challenges
- IL-23 licenses the transition from preclinical autoimmunity to inflammatory arthritis through IL-17A-dependent mechanisms
- Neoantigen nanovaccines for cancer immunotherapy: design strategies, translational bottlenecks, and clinical prospects.
- Oxidative Stress, Post‐Translational Modifications, and Type 1 Diabetes Pathogenesis
BibTeX
@article{amer2026cells,
title = {{T cells in type 1 diabetes: mechanisms of β-cell autoimmunity, innate-adaptive immune crosstalk, and translational immunotherapy}},
author = {Bushra Amer and Mohammed Alnukhali and Albaraa Haidarah and Anis Ahmad},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1845336},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1845336/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - T cells in type 1 diabetes: mechanisms of β-cell autoimmunity, innate-adaptive immune crosstalk, and translational immunotherapy
AU - Bushra Amer
AU - Mohammed Alnukhali
AU - Albaraa Haidarah
AU - Anis Ahmad
PY - 2026
DA - 2026/10/19
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1845336
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1845336/full
AB - Type 1 diabetes (T1D) is an autoimmune disease in which immune responses drive the destruction of insulin-producing pancreatic β-cells, ultimately resulting in lifelong insulin dependence. Although T cells are central mediators of β-cell autoimmunity, growing evidence shows that innate immune cells, including dendritic cells, macrophages, and natural killer (NK) cells, play essential roles in initiating, shaping, and sustaining pathogenic adaptive responses within the islet microenvironment. Both CD4 ⁺ helper and CD8 ⁺ cytotoxic T lymphocytes contribute to β-cell injury through the production of inflammatory cytokines, direct cytotoxicity, and disruption of self-tolerance. At the same time, regulatory T cells exhibit reduced numbers and/or impaired suppressive function, thereby further accelerating autoimmune progression. Recent advances in animal models, single-cell transcriptomics, spatial immune profiling, and T cell receptor sequencing have refined our understanding of autoreactive repertoires, antigen specificity, and bidirectional crosstalk between innate and adaptive immune compartments. At the translational level, immune signatures are emerging as tools for disease prediction and patient stratification, while therapeutic strategies ranging from anti-CD3 monoclonal antibodies to tolerogenic vaccines and adoptive Treg therapies are moving from preclinical development into clinical evaluation. The clinical success of teplizumab as the first disease-modifying therapy for T1D reinforces the value of targeting immune pathways, but durable remission across diverse patient groups remains a major challenge. This review synthesizes recent advances in the immunobiology of T cells in T1D, emphasizing their functional interplay with innate immune cells, tracing the path from mechanistic discovery to clinical translation, and highlighting future directions for precision immunotherapy.
SN - 1664-3224
ER -